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ABSTRACT
Objective: To assess the utilization and consequences of upper extremity Duplex ultrasound in the initial diagnostic
evaluation of patients with suspected subclavian vein (SCV) thrombosis and venous thoracic outlet syndrome (VTOS).
Methods: A retrospective single-center review was conducted for patients that underwent primary surgical treatment for
VTOS between 2008 and 2017, in whom an upper extremity ultrasound had been performed as the initial diagnostic test
(n ¼ 214). Clinical and treatment characteristics were compared between patients with positive and false-negative
ultrasound studies.
Results: There were 122 men (57%) and 92 women (43%) that had presented with spontaneous idiopathic arm swelling,
including 28 (13%) with proven pulmonary embolism, at a mean age of 30.7 6 0.8 years (range 14-69). Upper extremity
ultrasound had been performed 23.8 6 12.2 days after the onset of symptoms, with conﬁrmation of axillary-SCV
thrombosis in 169 patients (79%) and negative results in 45 (21%). Of the false-negative ultrasound study reports, only 8
(18%) acknowledged limitations in visualizing the central SCV. Deﬁnitive diagnostic imaging (DDI) had been obtained by
upper extremity venography in 175 (82%), computed tomography angiography in 24 (11%), and magnetic resonance
angiography in 15 (7%), with 142 (66%) undergoing catheter-directed axillary-SCV thrombolysis. The mean interval be-
tween initial ultrasound and DDI was 48.9 6 14.2 days with no signiﬁcant difference between groups, but patients with a
positive ultrasound weremore likely to have DDI within 48 hours than those with a false-negative ultrasound (44% vs 24%;
P ¼ .02). At the time of surgical treatment, the SCV was widely patent following paraclavicular decompression and
external venolysis alone in 74 patients (35%). Patch angioplasty was performed for focal SCV stenosis in 76 (36%) and
bypass graft reconstruction for long-segment axillary-SCV occlusion in 63 (29%). Patients with false-negative initial
ultrasound studies were signiﬁcantly more likely to require SCV bypass reconstruction than those with a positive ultra-
sound (44% vs 25%; P ¼ .02).
Conclusions: Duplex ultrasound has signiﬁcant limitations in the initial evaluation of patients with suspected SCV
thrombosis, with false-negative results in 21% of patients with proven VTOS. This is rarely acknowledged in ultrasound
reports, but false-negative ultrasound studies have the potential to delay deﬁnitive imaging, thrombolysis, and further
treatment for VTOS. Initial false-negative ultrasound results are associated with progressive thrombus extension and a
more frequent need for SCV bypass reconstruction at the time of surgical treatment. (J Vasc Surg: Venous and Lym Dis
2020;8:118-26.)
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Upper extremity deep vein thrombosis (UE-DVT) is rela-
tively uncommon, representing only 10% of all DVT, and
is most frequently associated with an underlying second-
ary cause, such as a central venous catheter, pacemaker
wire, malignancy, or pro-thrombotic hematological
condition.1-3 In contrast, idiopathic “primary” UE-DVT is
estimated to occur in approximately 20% to 30% of
patients. The most prevalent form of primary UE-DVT is
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due to extrinsic compression of the central subclavian
vein (SCV) at the level of the costoclavicular space, also
termed venous thoracic outlet syndrome (VTOS), which
leads to SCV “effort” thrombosis (Paget-Schroetter
syndrome).4
The pathophysiology of VTOS is currently understood to
involve repetitive dynamic compression and localized
injury of the SCV between the ﬁrst rib, clavicle, anterior
scalene muscle, subclavius muscle, and the costoclavicu-
lar ligament.4-6 Gradual ﬁbrous constriction of the SCV is
accompanied by expansion of collateral vein pathways,
such that patients are typically asymptomatic during
early stages of this condition. Eventually, thrombosis
occurs in the narrowed SCV, along with thrombus prop-
agation into the axillary vein and obstruction of critical
venous collaterals, resulting in abrupt clinical symptoms.
SCV thrombus forming central to the point of obstruc-
tion may also lead to pulmonary embolism, but this is
rarely hemodynamically signiﬁcant and usually asymp-
tomatic. The onset of upper extremity symptoms is
frequently perceived to be associated with recent exer-
tion, heavy lifting, or repetitive vigorous overhead use of
the upper extremity, which historically gave rise to the
term “effort” thrombosis; however, SCV thrombosis is bet-
ter viewed as an acute or subacute event superimposed
on chronic gradual venous obstruction. VTOS thereby
represents a “mechanical” anatomical condition second-
ary to vein compression and injury that is amenable to
surgical treatment, rather than a hematological condi-
tion to be managed primarily by anticoagulation.
Clinical suspicion of axillary-SCV thrombosis resulting
from VTOS is typically prompted by presentation of an
otherwise healthy, relatively young person with the sud-
den, spontaneous, onset of whole-arm swelling, with or
without cyanotic discoloration, in the absence of a
known malignancy, central venous catheter, recent arm
injury or surgery, or history of DVT.7 Prompt diagnosis of
VTOS is important to direct initial anticoagulation and
catheter-based venography within a timeframe that per-
mits the potential use of thrombolytic treatment (ideally
within 6-8 weeks after the onset of symptoms), as an in-
termediate step toward deﬁnitive surgical treatment.8-16
Duplex ultrasound has been described to have a high
level of sensitivity and speciﬁcity in the diagnosis of UE-
DVT and is widely considered the standard for initial eval-
uation of this condition.17-21 However, even the strongest
advocates of venous ultrasound acknowledge that “.an
important limitation of ultrasonography is that visualiza-
tion and compression of the subclavian and brachioce-
phalic veins are hampered by the clavicle, which limits
the accuracy of ultrasonography in these segments.”21
This limitation makes ultrasonography unsuited for early
diagnosis of VTOS, when focal central SCV obstruction
has not yet led to distal thrombus extension, and its
widespread use raises the likelihood that VTOS will be
unrecognized and undertreated. In a previous study of
competitive athletes with VTOS, we found that 21 of 32
patients (66%) had a duplex ultrasound as the initial
diagnostic study, with false-negative results in 29%.22
Although this raises concern that a false-negative ultra-
soundmight be associated with treatment delay and un-
satisfactory outcomes, there is otherwise little
information available on ultrasound in evaluation of
patients found to have axillary-SCV thrombosis resulting
from VTOS.
The purpose of this study was to better assess the utili-
zation and consequences of using upper extremity ultra-
sound in the initial evaluation of patients with suspected
SCV thrombosis and VTOS. To address these issues, we
examined clinical and treatment characteristics in a rela-
tively large series of patients that underwent surgical
treatment for VTOS, in whom an upper extremity ultra-
sound had been performed as the initial diagnostic
test, and compared these features between patients
with positive and false-negative ultrasound studies.
METHODS
The study population was derived from patients
referred to the Washington University Center for Thoracic
Outlet Syndrome at Barnes-Jewish Hospital (St. Louis,
Mo) for evaluation and surgical treatment of VTOS be-
tween January 2008 and March 2017. Patients with the
neurogenic or arterial forms of TOS were excluded from
review, as were patients with VTOS undergoing reopera-
tive procedures or operations for threatened hemodialy-
sis access. Detailed information regarding each patient
was obtained from a prospectively maintained database
and summarized from ofﬁce notes, hospital charts, imag-
ing studies, operative ﬁndings and records from treating
physicians, therapists, and vascular laboratories. The
study protocol and informed consent were approved
by the Human Research Protection Ofﬁce at Washington
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University in St. Louis; each patient provided written
informed consent.
Data were collected regarding the initial symptoms
and clinical presentation of each patient. Printed ultra-
sound reports were evaluated for the methods used to
identify DVT or venous ﬂow abnormalities, the speciﬁc
veins involved, and the presence of any statements
regarding limitations of the ultrasound study. Certiﬁca-
tion status of the speciﬁc laboratories performing each
ultrasound study were obtained by accessing the Inter-
societal Accreditation Commission (IAC) website
(https://www.intersocietal.org/iac/facilitylist/search.htm).
The timing, ﬁndings, and results of deﬁnitive diagnostic
imaging (DDI) studies, such as catheter-based venog-
raphy, computed tomography angiography (CTA) or
magnetic resonance angiography, and any catheter-
directed thrombolytic treatment, were determined
from printed reports of the relevant investigations and
procedures.
Patients were maintained on anticoagulation following
evaluation for surgical treatment of VTOS, including
physical examination and review of the most recent
venography studies. The level of functional disability
was assessed using the 11-item version of the Disabilities
of the Arm, Shoulder, and Hand (QuickDASH) survey in-
strument, which has been designed and validated for
use in a variety of upper extremity disorders including
TOS. Surgical treatment for VTOS was generally recom-
mended within 4 to 6 weeks of thrombolytic therapy to
allow time for resolution of acute perivenous inﬂamma-
tion while minimizing the risk of rethrombosis.
All patients underwent standardized paraclavicular
thoracic outlet decompression, including complete
anterior and middle scalenectomy, mobilization of the
brachial plexus nerve roots, subclavius muscle resection,
and complete ﬁrst rib resection from the transverse pro-
cess posteriorly and to the level of the sternum anteri-
orly.23,24 Exposure through the infraclavicular incision
was used to initiate external venolysis of the axillary-
SCV, which was then continued through the supraclavic-
ular incision to the junction of the SCV with the internal
jugular and innominate veins. Inspection, palpation, and
intraoperative venography were used to assess the
axillary-SCV and direct vein reconstruction was per-
formed if necessary, using patch angioplasty for focal ste-
nosis or bypass graft placement for long-segment
occlusion, as previously described.23,24 For occlusions
extending into the distal axillary vein, concomitant pec-
toralis minor tenotomy was used to identify a suitable
inﬂow vein for bypass graft reconstruction. No patients
required division of the sternocleidomastoid muscle, par-
tial resection of the clavicle, disruption of the sternocla-
vicular joint, or transmanubrial extension of the exposure.
Descriptive group data are presented as the mean 6
standard error or the frequency (percent incidence).
Comparisons between two groups were made using
the unpaired t-test with Welch correction (for data with
continuous variables) or Fisher’s exact test (for categori-
cal data). All statistical tests were performed using Prism
version 4.0c (GraphPad Software Inc, San Diego, Calif),
with P values < .05 considered signiﬁcant.
RESULTS
There were 339 patients that underwent primary opera-
tions for VTOS in our institution between January 2008
and March 2017, representing 21% of 1630 surgical pro-
cedures performed for all forms of TOS (Fig 1, A). There
were 255 patients with VTOS (75%) that had undergone
upper extremity ultrasound as the initial diagnostic test,
with incomplete data for 41 (only verbal results or insufﬁ-
ciently detailed reports), leaving 214 patients available for
the purposes of this study.
The study population consisted of 122 men (57%) and
92 women (43%) with a mean age of 30.7 6 0.8 years
(median 28.0, range 14-69). The age distribution of pa-
tients included 54 (25%) younger than age 21 and 160
(75%) older than age 21, with 95% younger than 55 years
of age (Fig 1, B). The majority of patients were right-hand
dominant (n ¼ 191; 89%) with the dominant side affected
in 153 (71%). Patients in the study population described
their primary occupation as student (n ¼ 42; 20%),
ofﬁce-based deskwork (n ¼ 42; 20%), athlete (n ¼ 41;
19%), skilled labor (n ¼ 24; 11%), nurse or therapist (n ¼
15; 7%), manager (n ¼ 12; 6%), homemaker (n ¼ 9; 4%),
manual labor (n ¼ 7; 3%), physician (n ¼ 7; 3%), unem-
ployed (n ¼ 7; 3%), or executive (n ¼ 5; 2%). There were
55 patients (26%) referred from the St. Louis metropol-
itan area, 105 (49%) from the central Midwest region,
and 54 (25%) from more distant locations in the United
States. The presenting symptoms consisted of arm
swelling alone in 122 (57%) and arm swelling with
cyanotic discoloration in 92 (43%), with 118 patients
(55%) initially presenting to an emergency room and 96
(45%) to a primary care physician. There were 28 patients
(13%) with radiographic evidence of pulmonary embo-
lism. The overall mean QuickDASH score upon referral
was 26.2 6 1.6.
Using SVS reporting standards deﬁnitions, the timing of
clinical presentation was characterized as acute (0 to
14 days) in 195 patients (91%), subacute (14 to 90 days)
in 9 patients (4%), and chronic (>90 days) in 10 patients
(5%).25 The mean time interval between the onset of
arm swelling symptoms and the initial ultrasound was
23.8 6 12.2 days. The upper extremity ultrasound per-
formed at initial presentation was positive in 169 patients
(79%) and negative in 45 (21%).
The positive ultrasound study reports described the dis-
tribution of DVT in both the axillary and subclavian veins
(n ¼ 59; 35%); the subclavian vein alone (n ¼ 52; 31%); the
basilic, axillary, and subclavian veins (n ¼ 41; 24%); the
basilic and axillary veins (n ¼ 5; 3%); the axillary vein alone
(n ¼ 2; 1%); ﬂow abnormalities consistent with proximal
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obstruction but no deﬁned thrombosis (n ¼ 4; 2%); and
unspeciﬁed (n ¼ 6; 3%). Thirteen (8%) of the positive ul-
trasound study reports indicated the potential presence
of SCV compression within the thoracic outlet. Of the
false-negative ultrasound study reports, only 8 (18%)
included a description of limitations of the study to visu-
alize the central SCV or the possibility of central venous
obstruction at the thoracic outlet, although 14 (31%) of
the laboratories performing these studies had current
IAC certiﬁcation for vascular testing. There were no signif-
icant differences between the positive and false-negative
ultrasound groups with regard to age, gender, side
affected, pattern or timing of symptomatic presentation,
incidence of pulmonary embolism, or QuickDASH scores
(Table I).
For the overall study population, DDI was obtained by
catheter-based upper extremity venography in 175
(82%). CTA was performed in 24 (11%) and magnetic
resonance angiography in 15 (7%) patients, primarily
when there had been longstanding symptoms. The inter-
val between the initial ultrasound and DDI was 48.9 6
14.2 days and the interval between the onset of symp-
toms and DDI was 72.7 6 18.7 days. There were only 86
patients (40%) that had DDI within 48 hours of ultra-
sound examination, whereas there were 58 (27%) in
whom DDI was performed more than 14 days after the
initial ultrasound. Venous thrombolysis was performed
in 142 patients (66%), with inclusion of balloon angio-
plasty in 115 (54%). There were no signiﬁcant differences
between the positive and false-negative ultrasound
groups with regard to the interval between symptoms
and initial ultrasound, the interval between initial ultra-
sound and DDI, the proportion of patients having DDI
within 14 days of the onset of symptoms or the initial ul-
trasound, or the proportion of patients undergoing
thrombolysis or balloon angioplasty treatment; however,
Fig 1. Derivation of the study population. A, Pie chart showing the proportion of patients undergoing surgical
treatment for neurogenic (NTOS), arterial (ATOS), and venous (VTOS) thoracic outlet syndromes, with bar illus-
trating the number of primary and reoperative procedures for VTOS. The study population was composed of
patients having primary operations for VTOS that had an upper extremity ultrasound as the initial diagnostic test,
and for whom complete data were available for analysis (n ¼ 214). B, Histogram illustrating the age distribution of
VTOS patients in the study population (mean 6 standard error, 30.7 6 0.8 years; median, 28.0 years; range, 14-
69 years), with approximately 95% of patients <55 years of age.
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patients with a positive initial ultrasound were signiﬁ-
cantly more likely to have DDI performed within 48 hours
than those with a false-negative ultrasound (44% vs 24%;
P ¼ .02; Table II).
All patients were maintained on anticoagulation after
DDI with a mean interval between DDI and surgical
treatment of 68.2 6 7.5 days. For those that had under-
gone thrombolysis (n ¼ 142), the mean interval between
Table I. Presenting characteristics of 214 patients with subclavian vein thrombosis and venous thoracic outlet syndrome
that had undergone upper extremity ultrasound as the initial diagnostic test
U/S positive (n ¼ 169) U/S negative (n ¼ 45) P value
Age (years) 30.4 6 0.9 31.9 6 2.0 .495a
Male 99 (59) 23 (51) .400b
Right side affected 126 (75) 32 (71) .703b
Presented to ER vs PCP 96 (57) 22 (49) .400b
Local metropolitan area patient 44 (26) 11 (24) 1.00b
Regional area referral 86 (51) 19 (42) .319b
Distant (out-of-region) referral 39 (23) 15 (33) .178b
Acute presentation (0-14 days) 157 (93) 38 (84) .084b
Subacute presentation (14-90 days) 5 (3) 4 (9) .095b
Chronic presentation (>90 days) 7 (4) 3 (7) .442b
Arm swelling alone 94 (56) 28 (62) .499b
Swelling and cyanotic discoloration 75 (44) 17 (38) .499b
Pulmonary embolism 21 (12) 7 (16) .620b
Initial QuickDASH 26.4 6 1.8 25.7 6 3.4 .856a
ER, Emergency room; PCP, primary care physician; QuickDASH, 11-item version of the Disabilities of the Arm, Shoulder, and Hand survey instrument;
SCV, subclavian vein; U/S, ultrasound; VTOS, venous thoracic outlet syndrome.
Patients were identiﬁed that had primary surgical treatment for VTOS between 2008 and 2017 and had U/S performed as the initial diagnostic test
(n ¼ 214). For each item assessed, the data shown indicate the mean 6 standard error for continuous measures or the number of patients (%) for
categorical variables.
aUnpaired t-test.
bFisher’s exact test.
Table II. Diagnosis and initial treatment of 214 patients with subclavian vein thrombosis and venous thoracic outlet
syndrome
U/S positive (n ¼ 169) U/S negative (n ¼ 45) P value
Symptoms to U/S (days) 23.3 6 15.1 25.5 6 12.6 .911a
Symptoms to U/S >14 days 12 (7) 6 (13) .224b
Symptoms to U/S >90 days 7 (4) 3 (7) .442b
U/S to DDI (days) 43.0 6 13.8 71.1 6 43.9 .544a
U/S to DDI <48 hoursc 75 (44) 11 (24) .017b
U/S to DDI >14 days 44 (26) 14 (31) .351b
U/S to DDI >90 days 13 (8) 5 (11) .544b
Symptoms to DDI (days) 66.3 6 20.4 96.6 6 45.9 .549a
Symptoms to DDI >14 days 50 (30) 18 (40) .208b
Symptoms to DDI >90 days 20 (12) 7 (16) .461b
DDI Type: venogram 140 (83) 35 (78) .514b
DDI Type: MRA 11 (7) 4 (9) .525b
DDI Type: CTA 18 (11) 6 (13) .600b
Thrombolysis performed 114 (67) 28 (62) .595b
Balloon angioplasty 94 (56) 21 (47) .315b
CTA, Computed tomography angiography; DDI, deﬁnitive diagnostic imaging; IAC, Intersocietal Accreditation Commission; MRA, magnetic resonance
angiography; U/S, ultrasound; VTOS, venous thoracic outlet syndrome.
Patients were identiﬁed that had primary surgical treatment for VTOS between 2008 and 2017 and had U/S performed as the initial diagnostic test
(n ¼ 214). For each item assessed, the data shown indicate the mean 6 standard error for continuous measures or the number of patients (%) for
categorical variables.
aUnpaired t-test.
bFisher’s exact test.
cP < .05.
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thrombolysis and surgical treatment was 50.3 6 6.8 days:
27.2 6 4.7 days for local patients (n ¼ 40), 47.3 6 6.2 days
for regional referral patients (n ¼ 63) and 80.6 6 22.2 days
for distant referral patients (n ¼ 38). Each patient under-
went paraclavicular thoracic outlet decompression with
complete resection of the ﬁrst rib and external venolysis
of the axillary SCV. In 74 patients (35%), the axillary SCV
was widely patent, by visual inspection, palpation, and
intraoperative venography, following decompression
and external venolysis alone. In 76 patients (36%), there
remained a focal high-grade SCV stenosis that was
treated by patch angioplasty, whereas 63 patients (29%)
had a long-segment SCV occlusion for which axillary-
innominate vein bypass was performed. In 52 of these
patients (24%), the venous occlusion extended laterally
underneath the pectoralis minor muscle, such that pec-
toralis minor tenotomy was required to expose a patent
axillary vein of suitable caliber for bypass reconstruction.
Although there were no signiﬁcant differences between
the positive and false-negative ultrasound groups with
regard to the incidence of external venolysis alone or
patch angioplasty reconstruction, patients that had a
false-negative ultrasound as the initial diagnostic study
were signiﬁcantly more likely to require axillary-SCV
bypass than those who had a positive ultrasound as the
initial diagnostic test (44% vs 25%; P ¼ .017; Fig 2).
DISCUSSION
The approach to diagnosis and management of VTOS
varies between different physicians and institutions,
and the most effective strategy for this condition con-
tinues to elicit debate.5-7,26,27 In this study, we examined
the clinical presentation for a large number of patients
with proven VTOS to assess the utilization and conse-
quences of using upper extremity ultrasound in the
initial evaluation of patients with suspected SCV throm-
bosis. The most important ﬁndings were: (1) initial duplex
ultrasound studies were false negative in 21% of patients
with VTOS; (2) the incidence of documented pulmonary
embolism was 13%; (3) there were disappointingly long
intervals between symptom onset, clinical suspicion,
and deﬁnitive diagnosis; (4) patients with a positive initial
ultrasound were nearly twice as likely to have deﬁnitive
imaging performed within 48 hours than those with a
false-negative ultrasound; (5) there was relatively low uti-
lization of thrombolysis as part of initial management;
and (6) at the time of surgical treatment, patients with
a false-negative ultrasound as the initial diagnostic study
were signiﬁcantly more likely to have a long-segment
SCV occlusion requiring bypass reconstruction than
those who initially had a positive ultrasound.
Treatment protocols for idiopathic UE-DVT that are
based on anticoagulation alone are ﬂawed by extrapola-
tion from regimens designed for lower extremity DVT,
often not taking into account the mechanical (surgically
correctable) pathophysiology underlying VTOS. Studies
of treatment for VTOS with anticoagulation alone have
consistently demonstrated suboptimal outcomes,
whereas better outcomes for this condition are reported
with prompt SCV thrombolysis and deﬁnitive surgical
treatment.28 Based on the present study and other inves-
tigations, we have developed a comprehensive manage-
ment algorithm for the diagnosis and treatment of SCV
thrombosis (Fig 3).5,6 Satisfactory thrombolysis allows
Fig 2. Operative ﬁndings and surgical treatment in patients with venous thoracic outlet syndrome (VTOS). Bar
graphs illustrating the incidence of different operative ﬁndings and the surgical treatment performed for patients
with VTOS, depending on the use of upper extremity ultrasound as the initial diagnostic test (positive ultrasound,
black bars, n ¼ 169; false-negative ultrasound, white bars, n ¼ 45). *P ¼ .017, Fisher’s exact test. SCV, Subclavian vein;
U/S, ultrasound.
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clearing of clot from the axillary and distal subclavian
veins but is unlikely to be successful more than 6 to
8 weeks after the onset of symptoms. Prompt recogni-
tion of axillary-SCV thrombosis is therefore crucial to
direct patients toward early venography and thromboly-
sis. Hematologic and oncologic evaluations are generally
not needed in this population and should not delay
deﬁnitive imaging, thrombolysis, or surgery. The optimal
timing is still uncertain, but surgical treatment should
generally be performed within 4 to 6 weeks of thrombol-
ysis to minimize the chance of rethrombosis. Surgical
treatment within the same hospitalization as thromboly-
sis is also an acceptable approach.29 Once surgical
decompression has been achieved, direct or indirect
(endovascular) intervention to restore a patent
subclavian vein can be successfully undertaken, either
in the operating room or in a delayed manner through
interventional approaches, as described in some proto-
cols.5,6,26,27,30 The principal limitation in the treatment
of VTOS is for patients who have long-segment occlusion
of the SCV that persists despite adequate decompres-
sion; in nearly every published series, such patients repre-
sent 5% to 20% of those presenting for surgery.6
Although this situation is managed differently in
different protocols, there remain some patients who
cannot be satisfactorily treated and for whom long-
term anticoagulation may be the only remaining option.
Overall management of VTOS should consequently be
aimed at minimizing the number of patients with
chronic long-segment occlusions. The methods used in
Fig 3. Recommended management algorithm for patients presenting with suspected subclavian vein (SCV)
thrombosis. AxV, Axillary vein; CTA, computed tomography angiography; InnV, innominate vein; MRA, magnetic
resonance angiography; Rx, treatment; VTOS, venous thoracic outlet syndrome.
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the initial evaluation of patients with suspected axillary-
SCV thrombosis are therefore important to permit
prompt and effective treatment toward this goal, and a
negative duplex ultrasound should not be used to
exclude a diagnosis of VTOS.
There are inherent technical limitations in the use of
duplex ultrasound for evaluation of the central SCV.21
These include the abbreviated acoustic window through
which to visualize the SCV due to the overriding clavicle,
the inability to compress the SCV because of anatomic
constraints, the presence of large transverse collateral
veins that may be misinterpreted to represent the SCV,
and high ﬂow through venous collaterals that may mini-
mize hemodynamic alterations even in the presence of
central SCV obstruction. Although these limitations are
acknowledged by experts in the ﬁeld and in various pub-
lications, they are often overlooked in clinical practice
and only rarely mentioned in clinical ultrasound reports.
It is not clear that these limitations are unique to noncer-
tiﬁed vascular laboratories because 31% of the false-
negative ultrasound evaluations in this study were per-
formed in IAC-certiﬁed laboratories. The usefulness of ul-
trasound in the initial evaluation of patients with
suspected SCV thrombosis is thereby often misunder-
stood and overstated. Although not addressed in this
study, the same concerns exist for the use of ultrasound
in postoperative follow-up of patients after treatment for
VTOS, where reports describing SCV patency based
solely upon ultrasound should be interpreted with
caution.
Clinicians ordering upper extremity ultrasound testing
to exclude DVT may not be aware of the limitations of
these studies and, as found in the current study, the re-
ports of ultrasound testing infrequently state the limita-
tions in assessing the central SCV. This may lead
clinicians to forego further evaluation or specialist
referral when ultrasound testing is reported to be
“negative,” rather than treat with presumptive anticoa-
gulation and obtain deﬁnitive imaging. For patients
with SCV thrombosis and VTOS, this approach may
delay or eliminate the potential use of thrombolytic
therapy, resulting in propagation of thrombus from a
focal lesion to a long-segment axillary-SCV occlusion
that cannot be readily treated at the time of surgery.
Indeed, in this study the incidence of long-segment
SCV occlusion at the time of surgery was nearly twofold
higher in patients that had a false-negative ultrasound
at initial evaluation. Unfortunately, in this study, only
11% of the reports describing false-negative ultrasound
studies had included a statement of limitations. We
therefore recommend that vascular laboratory reports
and IAC guidelines reﬂect these concerns by more
clearly stating the limitations of ultrasound in assessing
the central SCV, especially when studies are otherwise
negative for DVT in the distal subclavian, axillary, basilic,
and brachial veins.
One of the main limitations of this study is that it is
retrospective in nature and the type of data collected
do not allow determination of the overall sensitivity,
speciﬁcity, or accuracy of upper extremity ultrasound
for UE-DVT. The incidence of false-negative ultrasound
studies was thereby higher than would be observed in
a broader screening study of all patients presenting
with arm swelling. Another limitation is that the initial
clinical presentation and diagnosis of SCV thrombosis
took place at diverse locations and practice settings
and by a variety of different physicians; thus, it was not al-
ways clear if the initial ultrasound examination was done
in an IAC-certiﬁed vascular laboratory or if each patient
was evaluated by a vascular specialist. We also did not
have access to complete descriptions of the methodol-
ogy used in the initial ultrasound examinations, being
limited to the information obtained from the printed ul-
trasound reports. Nonetheless, one of the main strengths
of this study is that it reﬂects real-world clinical practice
regarding the presentation of patients with possible
UE-DVT and VTOS. Additional strengths are that all pa-
tients underwent treatment with a standardized proto-
col involving complete thoracic outlet decompression
and ﬂexible SCV reconstruction, depending on operative
ﬁndings, and that there were a large number of study
subjects for a relatively uncommon condition. We cannot
expect to eliminate use of upper extremity ultrasound in
the initial evaluation of suspected SCV thrombosis and
possible VTOS, but hope our ﬁndings will bring more
attention to this issue by vascular laboratories and
specialists.
CONCLUSIONS
Duplex ultrasound is limited in the initial evaluation of
patients with suspected SCV thrombosis, with false-
negative results in 21% of patients with proven VTOS.
This is rarely acknowledged in ultrasound reports, but
false-negative ultrasound studies have the potential to
delay deﬁnitive imaging, thrombolysis, and further treat-
ment for VTOS. False-negative ultrasound results are
associated with progressive thrombus extension and a
more frequent need for SCV bypass reconstruction at
the time of surgical treatment. Our ﬁndings suggest
that one step toward improving the diagnosis and treat-
ment of SCV thrombosis would be to only employ ultra-
sound with understanding that a negative study should
not delay deﬁnitive imaging, thrombolysis, and surgical
intervention.
AUTHOR CONTRIBUTIONS
Conception and design: EB, AA, BR, RT
Analysis and interpretation: EB, AA, WO, BR, RT
Data collection: EB, AA, RT
Writing the article: EB, RT
Critical revision of the article: EB, AA, WO, BR, RT
Final approval of the article: EB, AA, WO, BR, RT
Journal of Vascular Surgery: Venous and Lymphatic Disorders Brownie et al 125
Volume 8, Number 1
Statistical analysis: EB, AA, RT
Obtaining funding: RT
Overall responsibility: RT
REFERENCES
1. Spiezia L, Simioni P. Upper extremity deep vein thrombosis.
Intern Emerg Med 2010;5:103-9.
2. Klitfod L, Broholm R, Baekgaard N. Deep venous thrombosis
of the upper extremity. A review. Int Angiol 2013;32:447-52.
3. Noyes AM, Dickey J. The arm is not the leg: pathophysiology,
diagnosis, and management of upper extremity deep vein
thrombosis. R I Med J 2013;100:33-6.
4. Sanders RJ, Hammond SL. Venous thoracic outlet syn-
drome. Hand Clin 2004;20:113-8.
5. Illig KA, Doyle AJ. A comprehensive review of Paget-
Schroetter syndrome. J Vasc Surg 2010;51:1538-47.
6. Vemuri C, Salehi P, Benarroch-Gampel J, McLaughlin LN,
Thompson RW. Diagnosis and treatment of effort-induced
thrombosis of the axillary subclavian vein due to venous
thoracic outlet syndrome. J Vasc Surg Venous Lymphat
Disord 2016;4:485-500.
7. Feinberg RL. Clinical presentation and patient evaluation in
VTOS. In: Illig KA, Thompson RW, Freischlag JA,
Donahue DM, Jordan SE, Edgelow PI, editors. Thoracic
Outlet Syndrome. London: Springer; 2013. p. 345-53.
8. Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome
treated with thrombolytics and immediate surgery. J Vasc
Surg 2007;45:328-34.
9. Carlon TA, Sudheendra D. Interventional therapy for upper
extremity deep vein thrombosis. Semin Intervent Radiol
2017;34:54-60.
10. Kreienberg PB, Chaug BB, Darling RC III, Roddy SP, Paty PSK,
Lloyd WE, et al. Long-term results in patients treated with
thrombolysis, thoracic inlet decompression and subclavian
vein stenting for Paget-Schroetter syndrome. J Vasc Surg
2001;33:S100-5.
11. SchneiderDB,DimuzioPJ, GordonRL,WilsonMW, LabergeJM,
Kerlan RK, et al. Combination treatment of venous thoracic
outlet syndrome: open surgical decompression and intra-
operative angioplasty. J Vasc Surg 2004;40:599-603.
12. Mahmoud O, Vikatmaa P, Rasanen J, Peltola E, Sihvo E,
Vikatmaa L, et al. Catheter-directed thrombolysis versus
pharmacomechanical thrombectomy for upper extremity
deep venous thrombosis: a cost-effectiveness analysis. Ann
Vasc Surg 2018;51:246-53.
13. Ozcinar E, Yaman ND, Cakici M, Baran C, Inan MB, Durdu S,
et al. Pharmacomechanical thrombectomy of upper ex-
tremity deep vein thrombosis. Int Angiol 2017;36:275-80.
14. Karkkainen JM, Nuutinen H, Riekkinen T, Sihvo E,
Turtiainen J, Saari P, et al. Pharmacomechanical throm-
bectomy in Paget-Schroetter syndrome. Cardiovasc Inter-
vent Radiol 2016;39:1272-9.
15. Lugo J, Tanious A, Armstrong P, Back M, Johnson B,
Shames M, et al. Acute Paget-Schroetter syndrome: does
the ﬁrst rib routinely need to be removed after thrombol-
ysis? Ann Vasc Surg 2015;29:1073-7.
16. van den Houten MM, van Grinsven R, Pouwels S, Yo LS, van
Sambeek MR, Teijink JA. Treatment of upper-extremity
outﬂow thrombosis. Phlebology 2016;31(1 Suppl):28-33.
17. Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity
and speciﬁcity of ultrasonography in the diagnosis of upper
extremity deep vein thrombosis: a systematic review. Arch
Intern Med 2002;162:401-4.
18. Di Nisio M, Van Sluis GL, Bossuyt MM, Buller HR, Porreca E,
Rutjes AWS. Accuracy of diagnostic tests for clinically sus-
pected upper extremity deep vein thrombosis: a systematic
review. J Thromb Haemost 2010;8:684-92.
19. Kleinjan A, Di Nisio M, Beyer-Westendorf J, Camporese G,
Cosmi B, Ghirarduzzi A, et al. Safety and feasibility of a
diagnostic algorithm combining clinical probability, D-
dimer testing, and ultrasonography for suspected upper
extremity deep venous thrombosis: a prospective manage-
ment study. Ann Intern Med 2014;160:451-7.
20. Sartori M, Migliaccio L, Favaretto E, Brusi C, Conti E,
Rodorigo G, et al. Whole-arm ultrasound to rule out sus-
pected upper-extremity deep venous thrombosis in out-
patients. JAMA Intern Med 2015;175:1226-7.
21. Kraaijpoel N, van Es N, Porreca E, Buller HR, Di Nisio M.
The diagnostic management of upper extremity deep
vein thrombosis: a review of the literature. Thromb Res
2017;156:54-9.
22. Melby SJ, Vedantham S, Narra VR, Paletta GA Jr, Khoo-
Summers L, Driskill M, et al. Comprehensive surgical man-
agement of the competitive athlete with effort thrombosis
of the subclavian vein (Paget-Schroetter syndrome). J Vasc
Surg 2008;47:809-20.
23. Thompson RW. Venous thoracic outlet syndrome: para-
clavicular approach. Op Tech Gen Surg 2008;10:113-21.
24. Thompson RW. Operative decompression using the para-
clavicular approach for venous thoracic outlet syndrome. In:
Illig KA, Thompson RW, Freischlag JA, Donahue DM,
Jordan SE, Edgelow PI, editors. Thoracic Outlet Syndrome.
London: Springer; 2013. p. 433-45.
25. Illig KA, Donahue DM, Duncan A, Freischlag JA, Gelabert H,
Johansen K, et al. Reporting standards of the Society for
Vascular Surgery for thoracic outlet syndrome. J Vasc Surg
2016;64:e23-35.
26. de Leon RA, Chang DC, Hassoun HT, Black JH,
Roseborough GS, Perler BA, et al. Multiple treatment algo-
rithms for successful outcomes in venous thoracic outlet
syndrome. Surgery 2009;145:500-7.
27. Gelabert HA. Differential diagnosis, decision-making, and
pathways of care in VTOS. In: Illig KA, Thompson RW,
Freischlag JA, Donahue DM, Jordan SE, Edgelow PI, editors.
Thoracic Outlet Syndrome. London: Springer; 2013. p. 379-90.
28. Thiyagarajah K, Ellingwood L, Endres K, Hegazi A, Radford J,
Iansavitchene A, et al. Post-thrombotic syndrome and
recurrent thromboembolism in patients with upper
extremity deep vein thrombosis: a systematic review and
meta-analysis. Thromb Res 2018;174:34-9.
29. Angle N, Gelabert HA, Farooq MM, Caswell DR, Freischlag JA,
Machleder HI. Safety and efﬁcacy of early surgical decom-
pression of the thoracic outlet for Paget-Schroetter syn-
drome. Ann Vasc Surg 2001;15:37-42.
30. Kim TI, Sarac TP, Orion KC. Intravascular ultrasound in
venous thoracic outlet syndrome. Ann Vasc Surg 2019;54:
118-22.
Submitted May 5, 2019; accepted Aug 11, 2019.
126 Brownie et al Journal of Vascular Surgery: Venous and Lymphatic Disorders
January 2020
